reports
Savara Announces New Employment Inducement Grant
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 5, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 20,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc....
Savara to Present at the H.C. Wainwright 26th Annual Global Investment...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 at 10:00am ET/7:00am PT. A live webcast of the presentation will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granu...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On August 15, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 20,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 20,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 20...
Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molg...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of an abstract for poster presentation at the European Respiratory Society (ERS) Congress 2024, taking place September 7-11, 2024, in Vienna, Austria. The Company is also sponsoring an Industry Symposium at the Congress. Details are as follows: Accepted Abstract Title: “Inhaled Molgramostim Improves Pulmonary Gas Exchange and Respiratory Health-Related Quality of Life (HRQoL) in Patients with Autoimmune Pulmonary Alve...
Savara Reports Second Quarter 2024 Financial Results and Provides Busi...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2024 and provided a business update. Recent Business Highlights Reported positive top line results from IMPALA-2, a pivotal, Phase 3 clinical trial of molgramostim nebulizer solution (molgramostim) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) — Statistically significant improvement in Percent Predicted Diffusing Capacity of the Lungs for Carbon Monoxide...
Savara Announces Pricing of $100.0 Million Underwritten Offering of Co...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 26,246,720 shares of its common stock at a price of $3.81 per share before deducting underwriting discounts and commissions, for total gross proceeds of approximately $100.0 million. All of the securities to be sold in the offering are being sold by Savara. The offering included the following investors: Bain Capital Life Sciences, Farallon Capital Management, Frazier Life Sciences, Wellington Management, N...
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achiev...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced positive results from the pivotal, Phase 3 IMPALA-2 clinical trial. IMPALA-2 is a 48-week, randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of molgramostim 300 mcg administered once daily by inhalation with matching placebo in adult patients with aPAP (). Molgramostim is an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The trial met its primary endpoi...
Savara to Host Investor Call to Discuss Top Line Results From Pivotal ...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it will host a conference call and webcast tomorrow, Wednesday, June 26, 2024, at 8:00am ET to discuss top line results from the pivotal, Phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of molgramostim, an inhaled form of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with aPAP. The Company plans to issue a press release sharing the top line results at approximately 6:30a...
Savara to Present at the Jefferies Global Healthcare Conference
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:00am PT/10:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophag...
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA. Savara’s partner, Trillium Health LLC, presented a poster on the laboratory blood test that was recently developed to aid in the diagnosis of aPAP. Below are summaries of the posters presented: Poster Board 701: “Healthcare Burden of Pulmonary Alveolar Proteinosis” presented by E. Lee, M.D., Ph.D.; sponso...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 15,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 2,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 I...
Savara Reports First Quarter 2024 Financial Results and Provides Busin...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. “The IMPALA-2 trial remains on-track and we look forward to reporting top line results by the end of the second quarter,” said Matt Pauls, Chair and CEO, Savara. “Following that, and assuming positive data, we expect to file a BLA in the first half of 2025. Importantly, with $143 million in cash and investments, we believe we are capitalized into ...
Savara to Present at the Citizens JMP Life Sciences Conference
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Citizens JMP Life Science Conference on May 14, 2024 at 6:00am PT/9:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage...
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosi...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the acceptance of two abstracts for poster presentation at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego, CA. “We look forward to seeing data presented at ATS on the significant healthcare burden facing aPAP patients, challenges for diagnosis, and the development of a novel laboratory-based autoantibody blood test that can provide a definitive diagnosis of aPAP,” said M...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees. On March 21, 2024, Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 125,000 shares of the Company’s common stock and restricted stock units (RSUs) covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara...
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Prov...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending December 31, 2023 and provided a business update. “We look forward to reporting IMPALA-2 top line results at the end of the second quarter and, assuming positive data, anticipate filing the BLA in the first half of 2025,” said Matt Pauls, Chair and CEO, Savara. “2023 was a year of strong execution that included the on-time, over-enrollment of the Phase 3 IMPALA-2 trial and an an...
Savara to Present at the Barclays 26th Annual Global Healthcare Confer...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024 at 5:00am PT/8:00am ET. A live webcast of the fireside chat will be available on Savara’s website at and will be archived for 90 days. About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocy...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On January 31, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 70,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 30,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2...
Savara to Present at Two Upcoming Healthcare Conferences
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participating at the following investor healthcare conferences: Guggenheim 6th Annual Biotechnology Conference February 7, 2024 at 8:30am PT/ 11:30am ET Fireside Chat St. Regis Hotel, New York City, NY Oppenheimer 34th Annual Healthcare Life Sciences Conference February 13, 2024 at 7:40am PT / 10:40am ET Corporate Presentation Virtual Conference A webcast of each presentation will be available through the Inve...
Savara Inc: 3 directors
Three Directors at Savara Inc sold after exercising options/gave away/sold 206,843 shares at between 0.000USD and 4.713USD. The significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.